Lung & Respiratory Disease Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

This Phase 3 trial studied tezepelumab, a new biologic medicine for adults with asthma who need daily oral corticosteroids to control their symptoms. The goal was to see if tezepelumab could reduce the need for these steroids, which often cause unwanted side effects when used long-term. Results from 125 participants across several countries suggest that this treatment may help improve asthma control while lowering reliance on oral steroids.

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

This study focused on the use of extracorporeal membrane oxygenation, or ECMO, a life-support technique for adults with severe COVID-19 causing lung failure or heart problems. Conducted in France with a large group of patients, it aimed to find out if ECMO could increase survival chances when standard treatments are not enough. The findings may help guide future care for critically ill COVID-19 patients.

Treating Exacerbations of Asthma With Oral Montelukast in Children

In this Phase 2 trial, researchers tested a higher dose of oral montelukast to treat children experiencing moderate to severe worsening of asthma symptoms. Conducted at a single U.S. center with 90 children enrolled, the study explored whether this treatment can better ease breathing difficulties during asthma attacks compared to usual care. Positive results could lead to improved options for managing asthma flare-ups in children.

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

This ongoing Phase 2 trial is evaluating recombinant human plasma gelsolin (rhu-pGSN) added to standard care for patients with moderate to severe ARDS caused by infections like pneumonia. ARDS is a serious lung condition that can be life-threatening. If successful, this treatment could improve survival and recovery for patients facing this critical illness. The study is recruiting up to 600 patients across multiple countries.

Microbiote's Evolution After Use of Nitrous Oxide on Pediatric Patient Needing Airway Samples

This Phase 3 trial investigated how nitrous oxide affects the respiratory microbiome in children with lung illnesses who needed airway samples taken. The study, completed in France with 23 young children, aimed to understand whether the gas used during sample collection changes the types of bacteria present. This knowledge might help improve diagnosis and treatment of respiratory infections in children.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.